Synthesis and SAR Studies of Fused Oxadiazines as γ-Secretase Modulators for Treatment of Alzheimer's Disease
Xianhai Huang, Alexei V. Buevich(Merck & Co., Inc., Rahway, NJ, USA (United States)), Xiaohong Zhu, Gioconda Gallo, Michael Czarniecki(Merck & Co., Inc., Rahway, NJ, USA (United States)), Anandan Palani, Wei Zhou(Cedars-Sinai Medical Center), Monica Vicarel, Mary Cohen-Williams, William J. Greenlee, Lixin Song, Robert Aslanian(Merck & Co., Inc., Rahway, NJ, USA (United States)), Hongmei Li(Shenyang Aerospace University), Lili Zhang(Northeast Agricultural University), Zhaoning Zhu(Merck & Co., Inc., Rahway, NJ, USA (United States)), Zhiqiang Zhao, Duane A. Burnett, Xiaoxiang Liu, Chad Bennett, George Sun(Merck & Co., Inc., Rahway, NJ, USA (United States)), Mihirbaran Mandal(Merck & Co., Inc., Rahway, NJ, USA (United States)), John W. Clader, Lynn A. Hyde(Merck & Co., Inc., Rahway, NJ, USA (United States)), Inhou Chu, Troy McCraken(Merck & Co., Inc., Rahway, NJ, USA (United States)), David Cole(Georgetown University), Dmitri Pissarnitski
Cited by 39
Related Papers
Correction: Corrigendum: The OncoPPi network of cancer-focused protein–protein interactions to inform biological insights and therapeutic strategies
|Nature Communications|2017|645
The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patients
|Science Translational Medicine|2016|416
A Green Chemistry Approach to Asymmetric Catalysis: Solvent-Free and Highly Concentrated Reactions
|Chemical Reviews|2007|353
MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition
|Journal of Pharmacology and Experimental Therapeutics|2015|336
Chemistry and Biology of Diazonamide A: First Total Synthesis and Confirmation of the True Structure
|Journal of the American Chemical Society|2004|199